The Innovation at a Glance

US11491222B2 introduces a method for treating lower back pain by administering a pharmaceutical composition that includes a therapeutically effective amount of an antibody specifically binding to nerve growth factor (NGF) or its antigen binding fragment. The focus on NGF, a critical mediator in pain signaling pathways, reflects a targeted approach to pain management that deviates from traditional analgesics. The patent emphasizes antibody-based therapeutics designed to interfere with the pain process at a molecular level, presenting a biologically sophisticated solution.

The Inventor & Company Behind It

The assignee, Regeneron Pharmaceuticals Inc, is a well-established player in the biotech field known for advanced biologics and antibody development. With a robust portfolio of therapies addressing diverse medical needs, Regeneron's expertise in antibody engineering provides a foundation for innovation in treating chronic conditions such as lower back pain. Their strategic focus on NGF antibodies positions them to capitalize on both scientific advances and unmet patient needs in pain management.

Market Opportunity

Lower back pain remains one of the leading causes of disability globally, driving substantial demand for effective, non-opioid treatments. The biologics market addressing pain is growing, propelled by increasing patient awareness and regulatory encouragement for safer alternatives. Regeneron's approach targets a validated pain pathway, which may enable differentiation from conventional small-molecule treatments and improve efficacy and safety profiles. The patent’s focus aligns with ongoing trends prioritizing targeted therapies with measurable clinical outcomes.

Growth Indicators

The patent has accrued 156 citations, indicating a strong influence and validation within scientific and intellectual property communities. Its Health Innovation Score (HIS) of 71.8 suggests considerable technical novelty and potential impact. Coupled with Regeneron's reputation, these metrics reveal meaningful momentum behind this therapeutic concept. The established regulatory frameworks for biologics further support a clear pathway towards market introduction.

Why IP Investors Are Watching

Investors should watch this patent as a key asset reflecting Regeneron's strategic positioning in the HEALTHTECH domain. The biologic approach targeting NGF is a well-understood mechanism with precedent, yet still offers room for differentiation and improved clinical profiles. Given the significant market for lower back pain treatments and increasing demand for innovative therapeutics, this patent could underpin future licensing, partnerships, or product developments. However, investors must also weigh potential competitive risks and evolving safety considerations inherent in NGF-targeting therapies.

Get the Full Analysis

For a comprehensive evaluation of US11491222B2 and its implications for Regeneron's portfolio and the broader pain management landscape, access the full patent intelligence report on the IPI Terminal platform. Detailed citation analysis, competitor benchmarking, and market forecasts provide a nuanced view tailored for sophisticated IP investors.